GLP-1 Drug May Outperform Insulin for a Rare Form of Diabetes in Adolescents

GLP-1 (glucagon-like peptide-1) drugs are widely known for weight loss, but they were first developed to treat diabetes and remain important therapies for managing the disease. New research suggests that one GLP-1 therapy may also be effective for a rare form of diabetes associated with the blood disorder transfusion-dependent beta-thalassemia.

In transfusion-dependent beta-thalassemia, lifelong blood transfusions can lead to iron overload, which may damage the pancreas and impair insulin production. The resulting diabetes can be particularly difficult to manage because pancreatic damage and insulin resistance may both contribute to abnormal blood glucose regulation.

A study by researchers from Ain Shams University in Egypt compared the GLP-1 receptor agonist dulaglutide with insulin in adolescents with transfusion-dependent beta-thalassemia and diabetes who had inadequate glycemic control with metformin. Published in Diabetologia in 2024, the findings suggest that dulaglutide may offer advantages for glucose control and several metabolic outcomes in this specific patient population.

Study compares dulaglutide and insulin

The researchers enrolled 80 adolescents aged 10 to 18 with diabetes associated with transfusion-dependent beta-thalassemia. Half received once-weekly dulaglutide injections, while the other half received daily insulin therapy.

Participants were followed for 24 weeks and were instructed not to make major changes to their usual lifestyles during the study period. Researchers monitored measures of blood glucose control and glucose variability to compare the two treatments.

By the end of the study, adolescents receiving dulaglutide showed greater improvements in several measures of glycemic control than those treated with insulin. The dulaglutide group spent more time within recommended glucose ranges and experienced larger reductions in average blood glucose measures.

Metabolic and safety advantages

Differences were also observed in body weight and metabolic measures. Participants receiving dulaglutide avoided the weight gain that can accompany insulin treatment, with some showing modest reductions in weight during the study.

The researchers also examined whether dulaglutide could influence iron-related measures and pancreatic function, both particularly relevant to beta-thalassemia. The results provided preliminary indications of improvement in some of these measures, although the authors emphasized that larger studies are needed before firm conclusions can be drawn.

Dulaglutide treatment was not associated with an increased risk of hypoglycemia in the study population. Taken together, the findings suggest that the treatment may provide an alternative approach to improving glucose stability in adolescents with this uncommon form of diabetes.

How GLP-1 drugs work

GLP-1 receptor agonists such as dulaglutide mimic the activity of a naturally occurring hormone involved in glucose regulation. They stimulate glucose-dependent insulin secretion, suppress glucagon release and slow gastric emptying, helping reduce increases in blood glucose after eating.

These effects have made GLP-1 receptor agonists established treatments for type 2 diabetes. Their effects on appetite and body weight have also led to their increasingly prominent role in obesity treatment.

Thalassemia-related diabetes presents a different therapeutic challenge because chronic iron overload can damage pancreatic cells involved in insulin production. The new findings suggest that dulaglutide may still improve glucose regulation despite this underlying pancreatic impairment.

This does not establish that the drug can reverse pancreatic damage or replace insulin in all patients with thalassemia-related diabetes. Instead, the results indicate that GLP-1 receptor agonism may provide another therapeutic pathway worth investigating in this uncommon condition.

Implications and next research steps

The authors described the trial as the first to evaluate dulaglutide in adolescents with diabetes associated with transfusion-dependent beta-thalassemia. The findings provide an early indication that GLP-1 therapy could potentially improve glycemic management while reducing some of the disadvantages associated with daily insulin treatment.

However, the study included only 80 participants and lasted 24 weeks. It therefore cannot establish the long-term effectiveness or safety of dulaglutide in this population, nor can it determine whether apparent changes in iron-related measures or pancreatic function persist over time.

Larger multicenter trials with longer follow-up will be needed to confirm the findings and investigate the mechanisms responsible for the observed effects. Researchers will also need to determine which patients are most likely to benefit and whether similar results occur with other GLP-1 receptor agonists.

GLP-1 therapies can cause gastrointestinal adverse effects, and their cost and availability may also limit their use in some settings. These considerations are particularly relevant when evaluating treatments for relatively rare diseases that already require substantial lifelong medical care.

For now, the Ain Shams University study suggests that dulaglutide could represent a promising additional treatment option for adolescents with diabetes associated with transfusion-dependent beta-thalassemia. If the findings are reproduced in larger and longer trials, GLP-1 receptor agonists could eventually broaden the therapeutic options available for this difficult-to-manage form of diabetes.